| http://www.w3.org/ns/prov#value | - Reasons to Watch: Although the size of Endo???s settlement is significantly smaller than other recent settlements for off-label marketing (e.g., a 2012 settlement with GlaxoSmithKline for $3 billion and a 2013 settlement with Johnson & Johnson for $2.2 billion), Endo is a much smaller company than the other pharmaceutical company defendants and the allegations against Endo only involved one drug.
|
